Zhu, Rui <br/><br/>
Population-based efficacy modeling of omalizumab in patients with severe allergic asthma inadequately controlled with standard therapy.  [electronic resource] 

 -  The AAPS journal  Apr 2013 
 - 559-70 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1550-7416 
<br/><br/><label>Standard No.: </label>10.1208/s12248-013-9463-9  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Anti-Asthmatic Agents--administration & dosage<br/>Antibodies, Anti-Idiotypic--administration & dosage<br/>Antibodies, Monoclonal, Humanized--administration & dosage<br/>Asthma--diagnosis<br/>Biomarkers--blood<br/>Breath Tests<br/>Child<br/>Computer Simulation<br/>Double-Blind Method<br/>Drug Administration Schedule<br/>Female<br/>Forced Expiratory Volume<br/>Humans<br/>Immunoglobulin E--blood<br/>Lung--drug effects<br/>Male<br/>Middle Aged<br/>Models, Biological<br/>Monte Carlo Method<br/>Nitric Oxide--metabolism<br/>Omalizumab<br/>Prospective Studies<br/>Spirometry<br/>Time Factors<br/>Treatment Outcome<br/>Young Adult